SciClone at hold by Jefferies

SciClone Pharmaceuticals, Inc. was rated at hold by Jefferies & Co., Inc. analyst Adam Walsh. Jefferies expects top-line results for the second pivotal U.S. phase 3 trial in HCV patients with early cirrhosis of the liver in June 2006. The analyst is not optimistic for a positive outcome due to the harder-to-treat population than the non-cirrhotic patients, in which Zadaxin showed little effect. SciClone reported a fourth-quarter 2005 loss per share of $0.04, three cents above Jefferies' and consensus estimates. Shares of the San Mateo, Calif., biopharmaceutical company were down 8 cents, or 2.85%, at $2.73 on volume of 533,383 shares versus the three-month running average of 687,051 shares. (Nasdaq: SCLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.